Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

PureTech Health plc

$17.42

-0.01 (-0.09%)

C 46Pipeline Score Fair Value Biotech · Clinical
Market Cap
425.80 M
EPS
-4.56
P/E Ratio
-
Value Trade
124.65 K
0.06 %
Week
-3.92 %
1 Month
-3.64 %
3 Month
10.88 %
6 Month
-67.08 %
5 Year
-47.21 %
All Time
Cash Data

  • Cash Position

    12.35 K

  • Monthly Burn

    12.35 K

  • Runway

    12,345 mo

Overview
Volume
7.18 K
52 Week Range
14.50 - 19.92
% held by Insiders
-
% held by Institutions
0.58 %
Enterprise Value
160.26 M
Total Shares
24.34 M
Short %
-
Float Shares
-
Company Description
Employees:56
https://www.puretechhealth.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Phase 3 data readout example
VE303 (Live Biotherapeutic Product) prevention of recurrent Clostridioides difficile infection (rCDI)
Phase 3
—

Subscribe to access the data.

Microbiome-Based Therapies
Digestive System
VE303 (Live Biotherapeutic Product) prevention of recurrent Clostridioides difficile infection (rCDI)
Phase 3
—

Subscribe to access the data.

Microbiome-Based Therapies
Digestive System
VE303 (Live Biotherapeutic Product) prevention of recurrent Clostridioides difficile infection (rCDI)
Phase 3
—

Subscribe to access the data.

Microbiome-Based Therapies
Digestive System
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
C46
Pipeline Score
$1.0B
Pipeline Value
Fair Value
Valuation Signal
5
Drugs Scored
2.4x
rNPV / MCap
Top 67%
Micro Cap
(rank 302 of 911)
Percentile Rank
PureTech Health plc carries a moderate pipeline score (46/100), with $4.4B risk-adjusted pipeline value, led by LYT-200 in Metastatic Cancer (Phase 2), across $158B in total addressable markets.
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
LYT-200
Small molecule		Metastatic CancerPhase 2NCT0466668810% $4.0B COMPLETED 44 - -Dec 1, 2024 -Feb 11, 2025
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
GlyphAllo
major depressive disorder
Phase 2b
2026-03-26

therapeutically relevant drug levels in humans

PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans

Read More
GlyphAllo
major depressive disorder
Phase 2b
2026-03-26

therapeutically relevant drug levels in humans

PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans

Read More
GlyphAllo
major depressive disorder
Phase 2b
2026-03-26

therapeutically relevant drug levels in humans

PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans

Read More
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in PRTC
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
PRTC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How PRTC ranks across every disease it competes in
Competitive Position is a premium feature
See how PRTC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial